Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is one of the most common types of cardiac amyloidosis. Amyloid cardiomyopathy more commonly affects men, elderly, and 3% to 4% of the African-American population. ATTR-CM suspicion and diagnosis is challenging; however, awareness of the disease is increasing, and best practices to identify it are being proposed. The approach to suspected cases of ATTR-CM relies on the presence of heart failure, red flag signs and symptoms, and age >65 or >70 for men and women respectively. Little is known about cases when it presents in early ages. Case: We report a 62-year-old African American male with past medical history of hyperlipidemia, prostate cancer, hypertension, bilateral carpal tunnel surgery that had debuted with a cardiac arrhythmia at age 55 and was diagnosed with heart failure several years later. Restrictive cardiomyopathy was suspected, and genetic screening was sent for ATTRm which confirmed a pathogenic trasnthyretin gene mutation. Endomyocardial biopsy was performed which confirmed cardiac amyloid deposition. Discussion: ATTR-CM is a rare disease with an increasing prevalence. Cases with out of proportion signs and symptoms of heart failure with preserved ejection fractions should raise the suspicion of ATTR-CM despite age.

1. Witteles, RM, Bokhari, S, Damy, T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Hear Fail. 2019;7(8):709-716.
Google Scholar | Crossref | Medline2. Gilstrap, LG, Dominici, F, Wang, Y, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail. 2019;12(6):e005407.
Google Scholar | Crossref | Medline3. Porcari, A, Merlo, M, Rapezzi, C, Sinagra, G. Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery. Eur J Intern Med. 2020;82:7-15.
Google Scholar | Crossref | Medline4. Alexander, KM, Orav, J, Singh, A, et al. Geographic disparities in reported US amyloidosis mortality from 1979 to 2015 potential underdetection of cardiac amyloidosis. JAMA Cardiol. 2018;3(9):865-870.
Google Scholar | Crossref | Medline5. Ferdows, NB, Aranda, MP, Baldwin, JA, Ferdows, SB, Ahluwalia, JS, Kumar, A. Assessment of racial disparities in mortality rates among older adults living in US rural vs urban counties from 1968 to 2016. JAMA Netw Open. 2020;3(8):e2012241.
Google Scholar | Crossref | Medline6. Connors, LH, Doros, G, Sam, F, Badiee, A, Seldin, DC, Skinner, M. Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. Amyloid. 2011;18(Suppl 1):157-159.
Google Scholar | Crossref | Medline7. Nativi-Nicolau, J, Sarswat, N, Fajardo, J, et al. Best practices in specialized amyloidosis centers in the United States: A survey of cardiologists, nurses, patients, and patient advocates. Clin Med Insights Cardiol. 2021;15:11795468211015230.
Google Scholar | SAGE Journals8. Sekijima, Y, Ueda, M, Koike, H, Misawa, S, Ishii, T, Ando, Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6.
Google Scholar | Crossref | Medline9. Maurer, MS, Bokhari, S, Damy, T, et al. Expert consensus recommendations for the suspicion and diagnosis of cardiac transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075.
Google Scholar | Crossref | Medline10. Chiou, A, Aman, E, Kesarwani, M. A case report of an infiltrative cardiomyopathy in everyday practice: a specific cause that cannot be missed in the elderly. Eur Heart J Case Rep. 2020;4(6):1-6.
Google Scholar | Crossref | Medline